Therapeutic Effect of Upadacitinib in Primary Sjgren's Syndrome
Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
This study is designed to explore the efficacy and safety of upadacitinib and clarify the influence on immune function in the treatment of primary Sjgren's Syndrome.